Zone-specific remodeling of tumor blood vessels affects tumor growth

Cancer

Volumn 110, Issue 10, 2007, Pages 2347-2362

  Tilki, Derya ^a   Kilic, Nerbil ^b   Sevinc, Sema ^c   Zywietz, Friedrich ^b   Stief, Christian G ^a   Ergun, Suleyman ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Krankenhaus Maria Hilf   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Blood vessel stabilization; Necrosis; Tumor; Ultrastructure; Vascular remodeling

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CELL ULTRASTRUCTURE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

BLOOD VESSELS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 36049043759     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23024     Document Type: Article

References (32)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
3. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med. 2003;3:643-651.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-936.
5. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87:1153-1155.
6. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48-50.
7. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med. 2001;164:S39-S45.
8. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
9. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70-74.
10. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.
11. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol. 1985;120:327-332.
12. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 1990;87:6624-668.
13. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994;59:471-482.
14. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
15. Ergun S, Tilki D, Oliveira-Ferrer L, Schuch G, Kilic N. Significance of vascular stabilization for tumor growth and metastasis. Cancer Lett. 2006;238:180-187.
16. Kilic N, Lauke H, Fiedler W, et al. Angiogenic switch and vascular stability in human Leydig cell tumours. Angiogenesis. 1999;3:231-240.
17. Hawighorst T, Skobe M, Streit M, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol. 2002;160:1381-1392.
18. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
19. Sagowski C, Tesche S, Zywietz F, Wenzel S, Metternich FU. The radioprotectors amifostine and sodium selenite do not modify the radiosensitivity of rat rhabdomyosarcomas. Onkologie. 2004;27:54-57.
20. Zywietz F, Reeker W, Kochs E. Tumor oxygenation in a transplanted rat rhabdomyosarcoma during fractionated irradiation. Int J Radiat Oncol Biol Phys. 1995;32:1391-1400.
21. Ergun S, Kilic N, Ziegeler G, et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell. 2000;5:311-320.
22. Kilic N, Ergun S. Methods to evaluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis. In: Brooks SA, Schumacher U, editors. Methods in Molecular Medicine: Metastasis Research Protocols, Cell Behavior In Vitro and In Vivo. Vol. 2. Totowa, NJ: Humana Press;2001:125-148.
23. Davidoff M, Schulze W. Combination of the peroxidase antiperoxidase (PAP)- and avidin-biotin-peroxidase complex (ABC)-techniques: an amplification alternative in immunocytochemical staining. Histochemistry. 1990;93:531-536.
24. Ergun S, Davidoff M, Holstein AF. Capillaries in the lamina propria of human seminiferous tubules are partly fenestrated. Cell Tissue Res. 1996;286:93-102.
25. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
26. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19:7-16.
27. Issbrucker K, Marti HH, Hippenstiel S, et al. p38 MAP kinase - a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 2003;17: 262-264.
28. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264:569-571.
29. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806-813.
30. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1: 149-153.
31. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006;5:1779-1787.
32. Ergun S, Kilic N, Wurmbach JH, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis. 2001;4:193-206.